PRESS RELEASE Psy-Fi TMS Announces Partnership with NEBA Health LLC: Offering NEBA Brainwave-based ADHD Test 

 Augusta, GA (October 13, 2020) – NEBA® Health, LLC announced Psy-Fi TMS is now a NEBA partner in Edina, MN offering the only FDA cleared brainwave-based ADHD assessment aid. 

About Clinic and About Clinician 

Dr. Varma is board certified by the American Board of Psychiatry and Neurology (ABPN) and has been working in the mental health field since 1993. He treats adults as well as children, adolescents, geriatric populations, and patients from various cultural backgrounds. 

Psy-Fi TMS provides personalized prescribing through salivary DNA testing and Vivitrol monthly injections for alcohol and opioid dependence. Dr. Varma is certified by the DEA to prescribe suboxone, subsolv and bunavail for opioid dependence. He prescribes compounded Ketamine nasal spray for Treatment Resistance Depression (TRD) and will refer patients for psychotherapy, psychological testing, hypnotherapy, medical cannabis, and other non-pharmacological interventions if appropriate. Psy-Fi TMS performs deep TMS using Brainsway for Depression and Obsessive-Compulsive Disorder. 

About NEBA® 
NEBA is a 15 to 20-minute test that integrates an EEG biomarker for ADHD into the clinical setting. Using NEBA, clinicians can significantly reduce the number of patients receiving ADHD treatment and management as the initial focus when another condition would potentially be the primary diagnosis. In the FDA validation study, NEBA reduced the potential for over-diagnosis from 34% to 3%. NEBA also provides confirmatory support for ADHD with an accuracy of 92%. Clinicians conduct their evaluation as in their regular practice using their usual assessment tools. NEBA uses EEG to separate ADHD patients into biomarker-based groups with clinical differences that allow validated recommendations to be offered to the clinicians. 

Dr. Steve Snyder, Vice President of Research and Development said “NEBA can help the clinician to confirm ADHD as primary diagnosis and can help the clinician to determine whether ADHD-like symptoms may be better explained by another primary condition. “A clinician using NEBA is more likely to converge upon diagnostic evaluation results of a multidisciplinary team. 

About NEBA Health 
NEBA® Health develops diagnostic tools to help clinicians improve the lives of children and families. We developed the first FDA cleared Neuropsychiatric Interpretative Electroencephalograph Assessment Aid (NIEA) — named NEBA®. We have a variety of programs including NEBA-Cares to provide need-based assistance. We have ongoing work in ADHD, depression, and dementia. NEBA is an ISO 13485 registered medical device developer. We are cleared for marketing in the USA as (K112711), CE marked, and Health Canada licensed. 

Contact 
Psy-Fi TMS 
Dr. Sujit R. Varma & Eli Sirotin 
(612)746-7347